ORSERDU 86 mg film-coated tablets, CT7001, ORSERDU 345 mg film-coated tablets clinical trials

A Phase 1b/2 Open-Label Study of Samuraciclib in Combination with Elacestrant in Participants with Metastatic or Locally Advanced Hormone-Receptor-Positive and Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer

This study looks at combining two drugs, samuraciclib and elacestrant, for people with advanced breast cancer. It aims to find the best dose and see how well the combination works and if it's safe.